Fresenius Medical Care AG

Fresenius Medical Care’s new Global Chief Medical Officer signals a strategic pivot toward value‑based dialysis, boosting tech investment, governance, and market share.

UBS upgrades Fresenius Medical Care to “Sell” amid margin pressure, weaker cash flow and regulatory headwinds—investors weigh its strong balance sheet against rising risks.

Fresenius Medical Care AG announces a forthcoming capital‑market communication, complying with EU regulation 596/2014 – investors await details on potential equity, debt or dividend moves.

Fresenius Medical Care confirms EU regulatory compliance, showcasing disciplined transparency and robust governance—key for investor confidence.

Fresenius Medical Care’s Q3 2025 earnings show a 9.4% income boost from cost cuts and modest U.S. growth, but rising regulatory risks and R&D cuts threaten long‑term gains.

Fresenius Medical Care AG has accelerated its FME Reignite strategy by increasing equity stakes in its operational units, positioning the company for long-term growth and success in the kidney-care market through innovation, diversified services, an…

Fresenius Medical Care AG has announced a share buy-back program aimed at returning value to its shareholders, which is expected to boost earnings per share and potentially increase the stock’s value, amidst a cautiously optimistic European market e…

Fresenius Medical Care AG’s stock price plummeted nearly 5% after a UBS analyst downgraded the company from ’neutral’ to ‘sell’, citing concerns over its US dialysis outlook and future earnings.

Fresenius Medical Care AG’s stock price has declined after UBS downgraded the company from ’neutral’ to ‘sell’, citing concerns over the U.S. dialysis market outlook.

Fresenius Medical Care’s stock price has risen in recent times, but analysts are divided on its future prospects, with some advising to sell and others to hold onto the stock.